Navigation Links
Kosan Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Epothilone KOS-1584 at ASCO

16 mg/m2. Grade 3 peripheral neuropathy was observed in only 2 patients. -- On the 3-week schedule, 3 patients received a 1-hour infusion (16 mg/m2) and no dose-limiting toxicity was observed. -- On the 3-week schedule, no Grade 3 diarrhea was seen in the 6 patients receiving the 3-hour infusion at 20 mg/m2. A Grade 3 increase in liver function tests was observed in a patient with progressive liver disease.

Dose escalation is continuing on both the 3-week, 3-hour infusion schedule (currently at 25 mg/m2) and on the 4-week, 3-hour infusion schedule (currently at 20 mg/m2).

A second Phase 1 trial is currently exploring a single 3-hour infusion every 3 weeks (36-42 mg/m2). In this trial partial responses have been observed in patients with pancreatic and ovarian cancers and signs of activity in approximately 25% of patients, including a partial response in a heavily-pretreated patient with ovarian cancer (6 prior therapies; 31% tumor shrinkage by RECIST; 53.7% CA125 decline at end of study) and stable disease in patients with pancreatic, ovarian, non-small cell lung cancers and sarcomas.

Roche and Kosan plan to advance KOS-1584/R1645 into Phase 2 trials in the second half of 2007. The final dose and schedules for the Phase 2 trials will be based on clinical activity, dose intensity, side effect profile and schedule compatibility with established chemotherapy regimens.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.

Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Kosan's proprietary formulation of ta
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
3. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
4. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
5. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
6. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
7. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
(Date:9/18/2014)... 18, 2014  A $3 million grant from The ... of Michigan to establish a national center of excellence ... for Aging Research at U-M will focus on exploiting ... the effects of aging and postpone diseases in animal ... can help develop medications that may help people live ...
(Date:9/18/2014)... NEWARK, N.J. , Sept. 18, 2014  Neurotrope, ... Larry D. Altstiel , M.D., Ph.D. to the Company,s ... of Dr. Altstiel fills a vacancy on the Board ... of the Nominating and Corporate Governance Committee and a ... Board.  He is also a member of Neurotrope,s Scientific Advisory ...
(Date:9/18/2014)... 2014  Spring Bank Pharmaceuticals, Inc., a clinical-stage ... of RNA viruses, today announced a research collaboration ... animal testing of the Company,s lead compound, SB ... Pathogens," against which currently there are no effective ... Bank,s proprietary Small Molecule Nucleic Acid Hybrid ...
Breaking Medicine Technology:$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 2$3 M grant funds Paul F. Glenn Center for Aging Research at the University of Michigan 3Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 2Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 3Larry D. Altstiel, M.D., Ph.D. Joins Neurotrope Board of Directors 4Spring Bank Pharmaceuticals Announces NIH Collaboration for Testing of SB 9200 Against Multiple Viral Pathogens 2
... 2011 Booth # 407 at The American ... NxStage® Medical, Inc. (Nasdaq: NXTM ), ... announced that its Medisystems division has won a ... Solution to Atlantic Dialysis Management Services centers. ...
... Digital Assent, provider of the award-winning PatientPad® self-service ... it has opened offices in Los Angeles, Chicago and New ... rapid increase in demand for the PatientPad across the country ... of our major markets," said Andrew Ibbotson, president and CEO ...
Cached Medicine Technology:NxStage Awarded Multi-Year Contract to Supply Atlantic Dialysis Management Services with Vasc-Alert Access Surveillance Solution 2NxStage Awarded Multi-Year Contract to Supply Atlantic Dialysis Management Services with Vasc-Alert Access Surveillance Solution 3Digital Assent Opens Offices in Los Angeles, Chicago and New York 2
(Date:9/18/2014)... 2014 (HealthDay News) -- Daily supplements of selenium or ... development of age-related cataracts among men, a new study ... or both could help prevent cataracts. To investigate this ... Harvard Medical School in Boston, and his colleagues examined ... vitamin E. The trial was initially designed to study ...
(Date:9/18/2014)... Lake City, UT (PRWEB) September 18, 2014 ... North America will be recognizing their shared fundraising impact ... on Thursday, Sept. 25. , The first-ever Dance Marathon ... more than $20 million projected to be raised by ... their community’s CMN Hospital. Donations generated through Dance Marathon ...
(Date:9/18/2014)... scientists have developed a new method to study Ebola ... The Wildlife Conservation Society (WCS)-led research, published today in ... the use of fecal samples from wild great apes ... the virus. This represents a new tool for performing ... way Ebola virus is studied and improve our understanding ...
(Date:9/18/2014)... Dangerous new pathogens such as the Ebola virus invoke ... such as the bubonic plague are still providing researchers ... infections. , In a study published online Sept. 18, ... Duke Medicine and Duke-NUS Graduate Medical School Singapore detail ... hitchhike on immune cells in the lymph nodes and ...
(Date:9/18/2014)... Technology Association of Georgia in collaboration ... TAG Social Savvy Awards this week at a special ... Center in Downtown Atlanta. The event celebrates Georgia’s best ... was honored with the 2014 TAG Social Savvy People’s ... innovators in 6 other award categories: , ...
Breaking Medicine News(10 mins):Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2Health News:250 Campuses Usher in School Year of Saving Kids’ Lives During First-Ever “Dance Marathon Day” on Sept. 25 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 3Health News:New insights on an ancient plague could improve treatments for infections 2Health News:Winners Honored at 2014 TAG Social Savvy Awards 2Health News:Winners Honored at 2014 TAG Social Savvy Awards 3
... A group of Northeast Ohio breast,cancer survivors continue to ... the disease by participating in the sport of Dragon ... canoeing, involves a team of 22,paddlers racing in 40-foot-long ... the team offers women living with breast cancer an,opportunity ...
... Increasing temperatures, carbon dioxide levels add to discomfort of ... Add increased suffering for people with ragweed allergies to ... new study suggests. , Recent research indicates that ... longer ragweed seasons and more concentrated pollen counts, says ...
... certain genotype more affected, study finds , , MONDAY, Aug. ... containing codeine may be unwittingly risking the health of ... indicates that a relatively rare genetic predisposition causes some ... than normal -- possibly harming the infant,s central nervous ...
... at menopause as well as a woman,s breastfeeding practices ... breast cancer. That was the conclusion of a new ... CANCER, a peer-reviewed journal of the American ... distinct and separate hormonal risk factors associated with different ...
... Bikes Belong and Humana, launches Freewheelin ... bike-sharing initiative ... Inaugural Ride, DENVER, Aug. 24 Bike-sharing officially,rolled into Denver ... date: Freewheelin. Leading 100 cyclists,through the streets of Denver, Mayor Hickenlooper ...
... Benefit Group, LLC announces iCan Insurance, LLC ("iCan Insurance", "iCan") ... Inc. , ... Boca Raton, FL ... iCan Insurance, LLC ("iCan Insurance", "iCan") is now offering major ...
Cached Medicine News:Health News:Dragon Dream Team Continues to Send Message of Hope a Year Later 2Health News:Climate Change Linked to Longer Pollen Seasons 2Health News:Taking Codeine While Breast-Feeding May Harm Infant 2Health News:Taking Codeine While Breast-Feeding May Harm Infant 3Health News:Breastfeeding, other factors may affect risk of breast cancer type 2Health News:Kicking Into High Gear: Nation's Largest Bike-Sharing Program Debuts at Democratic National Convention 2Health News:Kicking Into High Gear: Nation's Largest Bike-Sharing Program Debuts at Democratic National Convention 3Health News:Kicking Into High Gear: Nation's Largest Bike-Sharing Program Debuts at Democratic National Convention 4Health News:iCan Benefit Group, LLC Announces: Major Medical Division Now Offers Avalon Healthcare Products 2
Battery-driven vacuum system operates with a touch of a button....
... The D.O.R.C. Harmony Special Peristaltic phacoemulsification ... latest technology including individual programmability and remote ... system features a front panel with color ... LCD display for ease of use and ...
... an advanced ophthalmic system that integrates ... allowing surgeons to independently select either ... procedures.,The key feature of this futuristic ... that measures in-line vacuum pressure, ensuring ...
The D.O.R.C. CryoStar is the smart cryosurgical system that combines optimal performance with state-of-the-art automation. simple for O.R. staff to operate and maintain throughout every procedure....
Medicine Products: